Monovalent influenza H5N8 vaccine - GSK
Alternative Names: FLU Q-PAN H5N8; Monovalent Influenza A/Astrakhan/3212/2020-like virus vaccineLatest Information Update: 11 Oct 2024
At a glance
- Originator GSK
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Influenza virus infections
Most Recent Events
- 21 May 2024 GSK completes the phase I/II trial in Influenza virus infections (Prevention) in USA (IM) (NCT05975840)
- 11 Aug 2023 Preclinical trials in Influenza virus infections (Prevention) in United Kingdom (IM)
- 11 Aug 2023 GSK plans a phase I/II trial in Influenza A virus infections (Prevention) [IM,Injection] in July 2023 (NCT05975840)